

Global Collaborative centre for Medical Countermeasures

GCMC


A TechInvention Initiative

Enabling One Health through Bio-innovation

The gap and our solution

The 21st century has witnessed a wave of infectious disease outbreaks, having devastating impact on lives across the globe. In the past seven decades, at least 250 zoonotic diseases have been identified, that are responsible for an estimated 2.5 billion cases of illnesses and 2.7 million deaths worldwide each year.

During the early days of the coronavirus disease 2019 (COVID-19) pandemic, diagnostic kits, repurposed treatments, and vaccines were made accessible rather soon, because of solid foundation of rapid genomic sequencing. Despite these breakthroughs, millions of lives were lost, with long-term consequences for health systems and well-being.



Going forward, health experts have warned that a new, unidentified pathogen, referred to as 'Disease X,' has the potential to trigger a severe international epidemic, possibly causing 50 million deaths, which would be 20 times more lethal than the COVID-19 pandemic.

Medical countermeasures (MCMs)

The '100 Days Mission', a CEPI initiative, was endorsed by the G7 and G20 in 2021, with the aim of focusing attention on efficient and equitable preparation for future disease outbreaks. MCMs are broad spectrum of medical assets (encompassing vaccines, diagnostics, and therapeutics), which can play a pivotal role in blunting the morbidity and mortality during public health emergencies, thereby enabling pandemic preparedness.

WHO's call to action

Given the shift in the global response to pandemic preparedness, WHO's call to the industry is to:

Align activities with WHO's guidance to focus on R&D of priority pathogens

Facilitate technology transfers and ensure transparency along the value chain

Take a tailored approach to enable a more equitable distribution of products

Our solution

TechInvention Lifecare Pvt. Ltd. distinguishes itself as a unique Indian startup, supporting the 'One Health' concept by integrating three pivotal interventions: diagnostics, vaccines, and biotherapeutics, catering to both human and veterinary sectors.

To address WHO's call to action and CEPI's 100 days mission, TechInvention is setting up a 'Global Collaborative Centre for Medical Countermeasures (GCMC)', a state-of-the-art biotech facility dedicated to translational research and development, as well as manufacturing of MCMs encompassing these three interventions.

The center that is strategically located at Navi Mumbai, a meticulously planned city adjacent to Mumbai, India's financial powerhouse, will be home to a comprehensive infrastructure that will collectively facilitate the rapid and compliant production of vaccines, diagnostics, and biotherapeutics while protecting IP and ensuring adherence to global regulatory standards.



GCMC infrastructure

GCMC - From strain-to-supply

GCMC, acknowledged for its global significance at the World Local Production Forum organized by the World Health Organization, stands as a testimony to TechInvention's strategic foresight and global impact with it's commitment to innovative biosolutions.

This establishment will serve the needs of both public and private organizations, such as academic institutes, start-ups, MSMEs and R&D organizations to provide a comprehensive ecosystem, facilitating transition from basic R&D to pilot-GMP-scale production for pre-clinical/clinical batches.

GCMC's key features will enable the center to cater to the entire cycle of biologics development, from strain-to-supply.

Key features

- BSL-1/2 labs for accelerated R&D work
- **Bioinformatics facilities**
- GMP facility for vaccines and biologics
- IP and regulatory support for necessary
- QC and QA labs to support early scale-up
- Logistics and supply chain team



Dear Sved Saader Ahmed

The 2nd World Local Production Forum (WLPF), which we hosted from 6-8 November 2023 in The Hague, brought together a global network of more than a thousand delegates from different sectors. They were all committed to improving timely and equitable access to good quality, safe and effective health products worldwide, through sustainable local and regional production. From the positive feedback the WHO and the Government of the Netherlands received, we are happy to conclude that it was a valuable stepping stone for many in taking this important ambition forward.

We would like to thank you for your participation, which was very much appreciated and contributed to the success of this second edition of the forum.

We hope you had meaningful and inspiring days in The Netherlands and that the programme, the parallel panel discussions and the networking with people from all over the world inspired you. It is also our hope that the WLPF provided you with new ideas, perspectives, policies, experiences and connections to take home and put into practice in the coming years.

It is important that the WLPF initiative is taken forward and the implementation of the recommendations of the second forum are pursued to help build sustainable national and regional ecosystems and to strengthen capacity for local production and voluntary technology transfer on mutually agreed terms. All with the goal of improving timely, equitable and sustainable access to medicines and other health technologies.

The WLPF will reconvene in 2025 in the United Arab Emirates, and all relevant stakeholders are encouraged to strengthen their engagement and provide support to the WLPF and the implementation of its recommendations. Let us follow the example of the three organizations which shared their concrete pledges in the closing session:

- The Global Collaborative Centre for Medical Counter Measures and Emerging
- Biopharma Manufacturers Network, as presented by Syed Ahmed.
 Team Europe Initiative on Manufacturing and Access to Vaccines, Medicines and Health
 Technology in Africa (TEI MAV+), as presented by Jeanne Riqué, European Commission.
 Enabling regional supply of diagnostic tests in LMICs, as presented by Robert Matiru on

Biotechnology R&D **Manufacturing Ecosystem**

> **R&D ORGANIZATIONS** (Private & Public)

> > **ACADEMIA**

(Private & Public)

STARTUPS - MSMEs

Large established **Manufactures** (Local/MNCs)

> **CROs CDMOs**

Challenges

Pre-clinical batches GMP validation batches **GMP** clinical batches **BSL Levels**

Special equipment Technology platforms IBSC/RCGM/IEC IP/Regulatory

*Finished products/Bulk supply, Scale of operations/Training, **Technology Transfer**

Cost, Regulatory, Quality Assurance, IP Concerns

GCMC '1 Stop Solution'

Genomic Information

AI-ML-CB

Apt platform

POC-PCT

Pilot GMP-CT

Regulatory Filings

Technology Transfer



Our commitment to sustainability

As an organization, we are committed to bringing greater health equity to people and nations all over the world. We recognize the privilege of the role we can play in improving healthcare in emerging and developing regions, especially at the grassroots level.

Our 'Going Green' initiative prioritizes making all of our operations more environment friendly. This demonstrates our commitment to a more sustainable future and helps build a healthier working environment.



GCMC is envisioned to be a centre par excellence for independent researchers, academia, and industry to collaborate and enable translational research, development, and commercial-scale manufacture of high-priority MCMs.

It will stand as a beacon of hope where science, innovation, and collaboration converge to counter the looming crisis of prevailing, emerging, and re-emerging infectious diseases.

'Together...Lets Collaborate to Accelerate'





healthequity4all



TechInventionL



TechInventionL




connect@techinvention.biz



www.techinvention.biz







Enabling One Health through Bio-innovation